Navigation Links
First targeted and programmable nanomedicine to show clinical antitumor effects published
Date:4/4/2012

Cambridge, MA, April 4, 2012 BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, that are capable of up to a ten-fold increase in drug concentration at tumor sites, has published preclinical and clinical data in Science Translational Medicine showing promising effects in solid tumors and successful clinical translation of BIND-014, the first targeted and programmed nanomedicine to enter human clinical studies.

In the paper titled "Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile," BIND scientists describe BIND-014's ability to concentrate in tumors and provide preclinical and clinical data demonstrating efficacy, safety and pharmacological properties that are superior to and highly differentiated from the parent chemotherapeutic drug, docetaxel. BIND-014 is the first clinical-stage targeted therapeutic nanoparticle with programmable pharmacological properties, including particle circulation time, pharmacokinetic profile, biodistribution and release profile. BIND-014 has been shown to effectively target a receptor expressed in tumors to achieve high drug concentrations at the site of disease.

"These seminal data on BIND's first clinical stage Accurin, BIND-014, demonstrates for the first time that it is possible to generate medicines with both targeted and programmable properties that can concentrate the therapeutic effect directly at the site of disease, potentially revolutionizing how complex diseases such as cancer are treated," commented Omid Farokhzad, M.D, BIND Founder and Associate Professor, Harvard Medical School. "BIND's data are a giant leap forward in achieving the true promise of nanomedicine by enabling the design of therapeutics with highly-differentiated efficacy and safety that go above and beyond the capabilities of traditional drug
'/>"/>

Contact: Kathryn Morris
kathryn@theyatesnetwork.com
914-204-6412
The Yates Network
Source:Eurekalert

Page: 1 2 3 4

Related biology technology :

1. MiMedx Exceeds Revenue Goal for First Quarter of 2012
2. FirstMark Exhibiting at the American College of Cardiology 61st Annual Scientific Sessions & Expo
3. Expanded Findings for FirstMarks Completed Clinical Study for Predicting Near-Term (2-3 Years) MI
4. Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer
5. Researchers capture first-ever images of atoms moving in a molecule
6. Be One of the First to Experience Medtrack One View at the AUTM 2012 Annual Meeting
7. First Statewide Biotech Meeting Focuses on Patient Access, Innovation
8. Inaugural Meeting of the FirstMark Scientific Board of Advisors
9. AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001
10. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
11. Penn researchers build first physical metatronic circuit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... succeeded in measuring vibrational motion of a single molecule ... vibration of a single molecule differs from the behaviour ... performed at the University of California, Irvine, where post-doctoral ... as a visiting fellow under professor Vartkess A. Apkarian, ... was lead by Professor Eric O. Potma. The results ...
(Date:8/20/2014)... BOSTON , Aug. 20, 2014  PAREXEL International ... it will be presenting at the Baird Healthcare Conference ... President and Chief Financial Officer, will be making a ... p.m. EDT on Wednesday, Sept. 3, 2014. ... through the "Investors" section of PAREXEL,s website at ...
(Date:8/20/2014)... improve the health of your heart, researchers have discovered. ... a standard TENS machine like those designed to relieve ... the small raised flap at the front of the ... The stimulation changed the influence of the nervous system ... can drive failing hearts too hard. , Professor Jim ...
(Date:8/19/2014)... 19, 2014 Shimadzu Scientific Instruments ... Prominence-i and Nexera-i, adding to the company’s extensive ... functionality, an intuitive operating environment, and full automation, ... efficient workflow for conventional to ultra-high-speed analysis. ... and intelligent design so users can begin building ...
Breaking Biology Technology:Seeing a molecule breathe 2PAREXEL International To Present At Baird Healthcare Conference 2'Tickling' your ear could be good for your heart 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3
... SAN FRANCISCO, Calif., Dec. 5, 2011 diaDexus, Inc. ... company focused on the development and commercialization of patent-protected ... in cardiovascular disease, today said that it plans to ... & Metabolic Disorders Conference on Tuesday, December 6, 2010 ...
... Md., Dec. 2, 2011 Northwest Biotherapeutics (OTC.BB: NWBO) ... major clean-up of its balance sheet, removing $31.5 million ... (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ) ... at the end of the third quarter to $16.5 ...
... Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer ... bioimplants processed from human amniotic membrane, announced today ... Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference ... Chairman and CEO, William C. Taylor, President and ...
Cached Biology Technology:Northwest Bio Implements Major Balance Sheet Clean-Up 2Northwest Bio Implements Major Balance Sheet Clean-Up 3Northwest Bio Implements Major Balance Sheet Clean-Up 4Northwest Bio Implements Major Balance Sheet Clean-Up 5
(Date:8/20/2014)... of approximately 3 million infants, a team of scientists ... of Massachusetts Medical School, have shown that newborn screening ... across public health newborn screening programs. Data from 11 ... of the Journal of the American Medical Association ... in newborns is higher than previously thought and believed ...
(Date:8/20/2014)... discovered that acral melanomas the rare type of skin ... genetically distinct from other more common types of skin cancer, ... journal Pigment Cell & Melanoma Research . , Acral ... of the feet, nail-beds and other hairless parts of the ... caused by UV damage from the sun. , The team, ...
(Date:8/20/2014)... spiciness that is irresistible to some, but intolerable to ... their findings to develop a new drug candidate for ... inflammation or other problems. They reported their progress on ... in ACS, Journal of Medicinal Chemistry . , ... had pegged a compound called capsaicin as the active ...
Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3Scientists learn more about rare skin cancer that killed Bob Marley 2
... BOSTON A potential new way to fight obesity-related ... by investigators at the Case Western Reserve University School ... University, the Cleveland Clinic Foundation and Cornell University, discovered ... liver disease brought on by obesity. "The implications of ...
... Geosphere papers posted online 4 and ... Mapping), EarthScope, CHIRP (compressed high-intensity radar pulse), and IODP ... of the nature of Earth. New locations studied: Sakhalin, ... monument, Mxico; and Andalshatten batholith, central Norway. Geosphere ...
... the world over and could be in mortal danger because ... others not, even when exposed to the same environmental conditions? ... Field Museum of Natural History has a surprising answer: The ... coral bleaching due to the light-scattering properties of their skeletons. ...
Cached Biology News:Vitamin E identified as potential weapon against obesity 2Vitamin E identified as potential weapon against obesity 3Geosphere features top geoscience technology, including LiDAR, EarthScope, CHIRP, ALSM, and IODP 2Geosphere features top geoscience technology, including LiDAR, EarthScope, CHIRP, ALSM, and IODP 3Geosphere features top geoscience technology, including LiDAR, EarthScope, CHIRP, ALSM, and IODP 4Geosphere features top geoscience technology, including LiDAR, EarthScope, CHIRP, ALSM, and IODP 5Geosphere features top geoscience technology, including LiDAR, EarthScope, CHIRP, ALSM, and IODP 6Geosphere features top geoscience technology, including LiDAR, EarthScope, CHIRP, ALSM, and IODP 7Geosphere features top geoscience technology, including LiDAR, EarthScope, CHIRP, ALSM, and IODP 8Geosphere features top geoscience technology, including LiDAR, EarthScope, CHIRP, ALSM, and IODP 9Geosphere features top geoscience technology, including LiDAR, EarthScope, CHIRP, ALSM, and IODP 10Insights into deadly coral bleaching could help preserve reefs 2Insights into deadly coral bleaching could help preserve reefs 3
... X-Gal ,MOLECULAR BIOLOGY GRADE ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside C ... Cl N O 6 ,M.W.= ... ,Solution: Clear (2% in DMF) ,Biological ... and M13 ,Elemental Analysis: Agrees with ...
...
... MW: 34.2kDa Formulation: 10mM HEPES, pH ... dithiothreitiol with 50% glycerol Properites: For ... Certificate of Analysis for individual lots ... followed by gel filtration and Mono-S ...
Antibody Purification Specificity: Antibody Purification ...
Biology Products: